Skip to main content
. 2020 Dec 2;11:550201. doi: 10.3389/fpsyt.2020.550201

Table 2.

Distribution of seriousness criteria selected for the adverse events reported for Risperidone and Aripiprazole.

Seriousness criteria Aripiprazole Risperidone p
N (%) N (%)
Other medically important condition 1,175 (48.5) 5,592 (73.8) p < 0.05
Caused/prolonged hospitalization 480 (19.8) 931 (12.3) p < 0.05
Disabling 69 (2.8) 83 (1.1) p < 0.05
Results in death 15 (0.6) 18 (0.2) p < 0.05
Life threatening 13 (0.5) 10 (0.1) p < 0.05
Congenital anomaly 2 (0.1) 0 (0.0)